p53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival, and site

Clinical Cancer Research

Volumn 4, Issue 5, 1998, Pages 1227-1234

  Lenz, Heinz Josef ^a   Danenberg, Kathleen D ^a   Leichman, Cynthia G ^a   Florentine, Barbara ^a   Johnston, Patrick G ^b   Groshen, Susan ^a   Zhou, Linyun ^a   Xiong, Yi Ping ^a   Danenberg, Peter V ^a   Leichman, Lawrence P ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COLON CANCER; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THYMIDYLATE SYNTHASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 15444349773     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Johnston, P. G., and Allegra, C. J. Colorectal cancer biology: clinical implications. Semin. Oncol., 5: 418-432, 1995.
2. Fuchs, C. S., and Mayer, R. J. Adjuvant chemotherapy for colon and rectal cancer. Semin. Oncol., 5: 472-487, 1995.
3. Wingo, P., Tong, T., and Bolden, S. Cancer statistics, 1995. CA Cancer J. Clin., 45: 8-30, 1995.
4. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. J. Am. Med. Assoc., 264: 1444-1450, 1990.
5. Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., Veeder, M. H., and Mailliard, J. A. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J. Clin. Oncol., 13: 2936-2943, 1995.
6. Jen, J., Kim, H., Piantadosi, S., Liu, Z. F., Levitt, R. C., Sistonen, P., Kinzler, K. W., Vogelstein, B., and Hamilton, S. R. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N. Engl. J. Med., 331: 213-221, 1995.
7. Gang, Q., Ahnen, D., Fenoglio-Preiser, C., Loll, L., Bunn, P., and Feigl, P. k-ras mutation and p53 overexpression but not ploidy status predict clinical behavior of colon cancer. Gastroenterology, 110: A516, 1996.
8. Johnston, P. G., Liang, C. M., Henry, S., Chabner, B. A., and Allegra, C. J. The production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissues. Cancer Res., 51: 6668-6676, 1991.
9. Johnston, P. G., Fisher, E. R., Rockette, H. E., Fisher, B., Wolmark, N., Drake, J. C., Chabner, B. A., and Allegra, C. J. The role of thymidylate synthase expression in prognosis and outcome to adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol., 12: 2640-2647, 1994.
10. Harpole, D. H., Herndon, J. E., Wolfe, W. G., Iglehart, J. D., and Marks, J. R. A prognostic model of recurrence and death in stage I non-small lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res., 55: 51-56, 1995.
11. Isobe, T., Hiyama, K., Yoshida, Y., Fujiwara, Y., and Yamakido, M. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection. Jpn. J. Cancer Res., 85: 1240-1246, 1994.
12. Hsiao, M. H., Yu, A. L., Yeargin, J., Ku, D., and Haas, M. Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase. Blood, 83: 2922-2930, 1994.
13. Allred, D. G., Clark, G. M., Elledge, R., Fuqua, S. A. W., Brown, W., Chamness, G. C., Osborne, C. K., and McGuire, W. L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst. (Bethesda), 85: 200-206, 1993.
14. Silvestrini, R., Benini, E., Daidone, M. G., Veneroni, S., Boracchi, P., Cappelletti, V., Di Fronzo, G., and Veronesi, U. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J. Natl. Cancer Inst. (Bethesda), 85: 965-970, 1993.
15. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S. C., Nichols, P. W., Skinner, D. G., Jones, P. A., and Cote, R. J. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med., 331: 1259-1264, 1994.
16. Yoshimura, I., Kudoh, J., Saito, S., Tazaki, H., and Shimizu, N. p53 gene mutation in recurrent superficial bladder cancer. J. Urol., 153: 1711-1715, 1995.
17. Zeng, Z-S., Sarkis, A. S., Zhang, Z-F., Klimstra, D. S., Charytonowicz, E., Guillem, J. G., Cordon-Cardo, C., and Cohen, A. M. p53 nuclear overexpression: an independent predictor of survival in lymph-node positive colorectal cancer patients. J. Clin. Oncol., 10: 2043-2050, 1994.
18. Auvinen, A., Isola, J., Visakorpi, T., Koivula, T., Virtanen, S., and Hakama, M. Overexpression of p53 and long-term survival in colon carcinoma. Br. J. Cancer, 70: 293-296, 1994.
19. Yamaguchi, A., Nakagawara, G., Kurosaka, Y., Nishimura, G., Yonemura, Y., and Miyazaki, I. p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer and its prognostic significance. Br. J. Cancer, 68: 399-402, 1993.
20. Lenz, H-J., Leichman, C. G., Danenberg, K. D., Danenberg, P. V., Groshen, S., Cohen, H., Laine, L., Crookes, P., Silberman, H., Baranda, J., Garcia, Y., Li, J., and Leichman, L. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J. Clin. Oncol., 14: 176-182, 1996.
21. Lenz, H-J., Danenberg, K. D., Leichman, C. G., Hayashi, K., Metzger, R., Salonga, D., Kortes, V., Banerjee, D., Bertino, J. R., Groshen, S., Leichman, L., and Danenberg, P. V. p53 status and thymidylate synthase (TS) levels are predictors of chemotherapy efficacy. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 15: 504, 1996.
22. Leichman, L., Lenz, H-J., Leichman, C. G., Groshen, S., Danenberg, K., Baranda, J., Spears, C. P., Boswell, W., Silberman, H., Ortega, A., Stain, S., Beart, R., and Danenberg, P. Quantitation of intratumoural thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur. J. Cancer, 31: 1306-1310, 1995.
23. Johnston, P. G., Lenz, H-J., Leichman, C. G., Danenberg, K. D., Allegra, C. J., Danenberg, P. V., and Leichman, L. Thymidylate synthase protein and gene expression predicts for response to 5-fluorouracil/leucovorin chemotherapy in patients with colorectal and gastric cancer. Cancer Res., 55: 1407-1412, 1995.
24. American Joint Committee on Cancer. Manual for Staging of Cancer. Philadelphia: J. B. Lippincott Co., 1988.
25. Vasen, H. F. A., Mecklin, J-P., Kahn, P. M., and Lynch, H. T. Hereditary non-polyposis colorectal cancer. Dis. Colon Rectum, 35: 424-425, 1991.
26. Baas, I. O., Mulder, J-W. R., Offerhaus, G. J. A., Vogelstein, B., and Hamilton, S. R. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J. Pathol., 172: 5-12, 1994.
27. Mantel, N., and Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. (Bethesda), 22: 719-748, 1959.
28. Tarone, R. E. Tests for trend in life table analysis. Biometrika, 62: 679-682, 1975.
29. Miller, R. G. Survival Analysis, Sections 4.2, 3.2. New York: John Wiley & Sons, Inc., 1981.
30. Pike, M. C. Contribution to the discussion on the paper by R. Peto and J. Peto: asymptotically efficient rank invariant test procedures. J. R. Stat. Soc. A, 135: 201-203, 1972.
31. Berry, G., Kitchin, R. M., and Mock, P. A. A comparison of two simple hazard ratio estimators based on the logrank test. Stat. Med., 10: 749-755, 1991.
32. Lawless, J. F. Statistical Models and Methods for Lifetime Data, Section 7.2.1-7.2.2. New York: John Wiley & Sons, 1982.
33. Dukes, C. Cancer of the rectum: an analysis of 1000 cases. J. Pathol. Bacteriol., 50: 527-539, 1940.
34. Bosari, S., Viale, G., Bossi, P., Maggioni, M., Coggi, G., Myrray, J. J., and Lee, A. K. C. Cytoplasmatic accumulation of p53: an independent prognostic indicator in colorectal adenocarcinomas. J. Natl. Cancer Inst. (Bethesda), 86: 681-687, 1994.
35. Sun, X-F., Carstensen, J. M., Zhang, H., Stal, O., Wingren, S., Hatschek, T., and Nordenskjold, B. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet, 340: 1369-1373, 1992.
36. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
37. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
38. Moertel, C. G., Fleming, T. R., MacDonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., Veeder, M. H., and Mailliard, J. A. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Intern. Med., 122: 321-326, 1995.
39. Scott, N., Sagar, P., Stewart, J., Blair, G. E., Dixon, M. F., and Quirke, P. p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br. J. Cancer, 63: 317-319, 1991.
40. Remvikos, Y., Tominaga, O., Hammel, P., Puig-Laurent, P., Salmon, R. J., Dutrillaux, B., and Thomas, G. Increased p53 protein content of colorectal tumors correlates with poor survival. Br. J. Cancer, 66: 758-764, 1992.
41. Thibodeau, S., Bren, G., and Schaid, D. Microsatellite instability in cancer of the proximal colon. Science (Washington DC), 260: 816-819, 1993.
42. Chu, E., Copur, S., Jones, K. L., Khleif, S., Voeller, D., Maley, G. F., Maley, F., and Allegra, C. J. Thymidylate synthase regulates the translation of p53 mRNA. Proc. Am. Assoc. Cancer Res., 36: 563, 1995.